Satraplatin (Synonyms: BMS-182751, BMY 45594, JM 216) |
Catalog No.GC37593 |
El satraplatino es un agente alquilante, con un potente efecto antitumoral.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 129580-63-8
Sample solution is provided at 25 µL, 10mM.
Satraplatin is an alkylating agent, with potent antitumor effect.
Satraplatin has potent antitumor activity. Satraplatin combined with dichloroacetate (DCA) inhibits UMC-11 cells with an IC50 of 1.36 ± 0.11 μM[1]. Satraplatin also suppresses CDDP-resistant (KB-R) cells (IC50, 7.04 μM), and causes G2/M arrest in KB-R cells[2].
[1]. Fiebiger W, et al. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clin Transl Oncol. 2011 Jan;13(1):43-9. [2]. Yamano Y, et al. Antitumor activity of satraplatin in cisplatin-resistant oral squamous cell carcinoma cells. Head Neck. 2011 Mar;33(3):309-17.
Average Rating: 5
(Based on Reviews and 22 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *